ndothelin-1 (ET-1) is an endogenous vasoconstrictive peptide that increases blood pressure as well as the plasma concentrations of vasopressin, renin, aldosterone, epinephrine, norepinephrine, and atrial natriuretic peptide. 1 In addition, ET-1 acts as a growth factor inducing hypertrophy. 2 Furthermore, ET-1 exerts positive inotropic effects in rat, 3, 4 rabbit, 5, 6 and ferret 7 but not in guinea pig 8 or dog 6 myocardium. Recently, a local ET production in the heart has been demonstrated; it is secreted from the endocardium, the myocardium, and the coronary endothelium, 9,10 thereby acting in a paracrine and autocrine fashion on myocytes.
ET plasma levels are elevated in patients with chronic heart failure, 11, 12 and increased ET-1 levels participate in the maintenance of cardiac contractile function in rats with congestive heart failure. 13 Endogenous ET-1 contributes to the maintenance of vascular tone in healthy men 14 and to vasoconstriction in severe chronic heart failure. 15, 16 However, a possible functional role of ET-1 in the human heart remains to be elucidated. Despite controversial reports on the effects of ET-1 in mammalian myocardium, little is known about its direct actions in human myocardium. Qiu et al 17 showed a Ca 2ϩ -sensitizing effect of ET-1 in myocytes from failing human hearts, and Schömisch-Moravec et al 18 demonstrated a slight increase in force in muscle strips from failing hearts. However, both studies investigated only one concentration of ET-1 and made no comparison between nonfailing and failing myocardium. Autoradiographic studies have shown the existence of ET receptors in human atrial and ventricular myocardium but did not address the question of ET receptor regulation in heart failure. 19, 20 Recently, Pönicke et al 21 demonstrated both ET A and ET B receptors in human cardiac tissue by radioligand binding studies. ET-1 peptide has been detected in human myocardium, but no comparison between nonfailing and failing tissue was made. 22 Therefore, the goal of the present study was to characterize the inotropic effects of ET-1, the ET receptor subtype involved in this effect, and the subcellular mechanism of action of ET-1 in isolated myocardium from nonfailing and end-stage failing human hearts. Furthermore, possible alterations of ET receptors and ET-1 peptide concentrations in idiopathic dilative cardiomyopathy (DCM) were characterized.
Methods

Myocardial Tissue
Functional experiments were performed in isolated left ventricular muscle strips from 10 nonfailing human hearts that could not be transplanted for technical reasons and 27 end-stage failing hearts (DCM; ejection fraction, 22Ϯ1%). For biochemical analyses, transmyocardial specimens of left ventricular tissue (1 to 3 g), free of macroscopic fatty tissue and coronary arteries, were frozen in liquid nitrogen immediately after explantation and stored at Ϫ80°C. The study was approved by the Ethical Committee of the University Clinics of Freiburg.
Functional Measurements
Muscle Strip Preparation
Muscle strips were prepared as previously described, 23 
Experimental Protocol
After complete mechanical stabilization, cumulative concentrationresponse curves for ET-1 0.0001 to 0.3 mol/L or the specific ET B receptor agonist sarafotoxin S6c 0.001 to 0.3 mol/L were established. Additional experiments were performed after muscle strips had been preincubated for 30 minutes with prazosin 0.1 mol/L, propranolol 1 mol/L, the mixed ET receptor antagonist bosentan 3 and 30 mol/L, or the specific ET A receptor antagonist BQ-123 0.03 and 0.3 mol/L.
Aequorin Measurements
To assess the effects of ET-1 on intracellular Ca 2ϩ transients, muscle strips were loaded with the photoprotein aequorin as described previously. 23 Briefly, aequorin 1 to 3 L was macroinjected through a fine-tipped glass micropipette into the quiescent muscle. Changes in aequorin light emission, reflecting changes in intracellular Ca 2ϩ transients, were detected by a photomultiplier (XP 2802, Philipps). Light emission (mV photomultiplier output) and isometric force (mN) were recorded simultaneously on an oscilloscope with signalaveraging function (Nicolet PRO 10C, Nicolet Instrument Corp) and on a chart recorder (WR 3310, Graphtec 
Radioligand Binding
Membrane Preparation
Microsomal membrane preparations and radioligand binding studies were performed as described in detail elsewhere. 24 Briefly, myocardial tissue was homogenized by use of a Polytron homogenizer PT-K (Brinkman Instruments) for 2 minutes in ice-cold buffer of the following composition (in mmol/L): Tris/HCl 5, MgCl 2 1, and sucrose 250; pH 6.4. After repeated centrifugation and rehomogenization steps, the resulting microsomal membrane homogenate was suspended in 1 mL incubation buffer (Tris/HCl 75 mmol/L, MnCl 2 25 mmol/L, sucrose 250 mmol/L, chymostatin 2 mg/L, leupeptin 4 mg/L, bacitracin 40 mg/L, pH 7.4), divided into aliquots, and stored at -80°C. 
Competitive Radioligand Binding
Endothelin-1 Peptide Expression
ET-1 peptide concentration in tissue homogenates was measured by radioimmunoassay (RIA) as described by Löffler and Maire. 25 Frozen tissue samples were thawed on ice and homogenized in a 10-fold wet weight volume of 0.9% NaCl solution and kept at 0°C to 4°C. Aliquots of 100 and 200 L were mixed with 1 mL methanol. Precipitated protein was sedimented at 3000g for 10 minutes. The methanol/water phase was evaporated to dryness and redissolved in RIA buffer, and ET-1 was determined as described. 25 ET extraction efficacy, as measured by spiking of homogenates with ET-1 10 to 100 pg, was determined to be Ͼ90%.
Materials
ET-1 (porcine/human; Sigma Chemical Co) was dissolved in deionized water in a concentration of 10 mol/L and stored at Ϫ80°C until use. BQ-123, sarafotoxin S6c, and isoproterenol hydrochloride were also obtained from Sigma. Bosentan was obtained from Hoffmann-La Roche.
Statistical Analysis
Average values are given as meanϮSEM. Comparison within one group of myocardium was performed by use of paired t test and Bonferroni-Holms equation. Comparisons between different groups were performed by ANOVA followed by Student-Newman-Keuls test. For analysis of binding data, the average from triplicate experiments under each condition was used. Differences were considered significant at PϽ0.05.
Results
Positive Inotropic Effects of ET-1 in Isolated Human Myocardium
ET-1 exerted clear positive inotropic effects in human myocardium. Figure 1 shows original recordings from typical experiments. In a nonfailing preparation (top panel), isometric force increased from 6.5 to 11.4 mN. In a preparation from a failing heart (bottom panel), the positive inotropic effect was less pronounced (increase from 4.9 to 6.4 mN). There was no initial depression of tension before the rise in twitch force, as has been previously described in atrial preparations. 26 The concentration-dependent inotropic response to ET-1 is shown in Figure 2 . In nonfailing myocardium, the effect started at a concentration of 0.001 mol/L and was maximal at 0.1 mol/L ET-1. At that concentration, force had increased by 5.3Ϯ1.2 mN/mm 2 , or 52Ϯ11% (PϽ0.05; nϭ10).
In DCM, the effect of ET-1 was likewise maximal at 0.1 mol/L. However, ET-1 increased force only by 3.0Ϯ0.5 mN/mm 2 , or 36Ϯ11% (PϽ0.05 versus baseline; nϭ14). At concentrations Ͼ0.01 mol/L, the positive inotropic effect was significantly more pronounced in nonfailing than in failing myocardium. Despite the reduced effectiveness of ET-1 in failing myocardium, its potency remained unchanged: the EC 50 was 4.28 nmol/L (CI, 1.25 to 14.67 nmol/L) in nonfailing and 3.42 nmol/L (CI, 1.52 to 7.66 nmol/L) in failing myocardium (PϭNS). ET-1 prolonged both time to peak and relaxation time in a concentrationdependent manner (Table 1) .
␣-Adrenergic receptor blockade with prazosin 0.1 mol/L and ␤-adrenergic receptor blockade with propranolol 1 mol/L did not affect the inotropic response to ET-1 in end-stage failing myocardium (increase in force by 31.7Ϯ9.9%; nϭ8; PϭNS versus data without antagonists, not shown). In contrast, the mixed ET receptor antagonist bosentan 3 and 30 mol/L shifted the concentration-response curves for ET-1 to the right, and at 30 mol/L bosentan, the maximal inotropic response to ET-1 was attenuated at the concentrations of ET-1 used (Figure 3, left) .
To test whether the inotropic effect of ET-1 is mediated via ET A or ET B receptors, experiments were performed after selective blocking of ET A receptors with BQ-123. BQ-123 at 0.03 and 0.3 mol/L shifted the concentration-response curve for ET-1 to the right, and with 0.3 mol/L BQ-123, the maximal inotropic effect of ET-1 was reduced (Figure 3,  right) . Furthermore, the selective ET B receptor agonist sarafotoxin S6c 0.001 to 0.3 mol/L did not elicit any inotropic effects in nonfailing or failing myocardium (Figure 4 ), whereas ET-1 at 0.1 mol/L applied after sarafotoxin S6c increased force to 181Ϯ20% and 139Ϯ18%, respectively (PϽ0.05 versus baseline for both groups). These data indicate that the functional effects of ET-1 are mediated exclusively via ET A receptors.
Aequorin Experiments
ET-1 increased twitch force with only slight changes in aequorin light emission. This can be seen from superimposed original tracings in aequorin-loaded muscle strips from a nonfailing ( Figure 5 , left) and a failing heart ( Figure 5, middle) . In contrast, a similar increase in twitch force in a muscle strip from a nonfailing heart after [Ca 2ϩ ] o was raised to 4 mmol/L was associated with a substantial increase in aequorin light emission ( Figure 5 , right). Figure  6 shows concentration-response curves for ET-1 in aequorin-loaded muscle strips from 5 nonfailing (left) and 7 DCM (right) hearts. In nonfailing myocardium, ET-1 resulted in a pronounced increase in force but only slight increases in aequorin light emission. In DCM, the maximal inotropic effect of ET-1 was smaller, and there were only minor changes in aequorin light emission. and from 60Ϯ8% to 153Ϯ8% in failing (nϭ6) myocardium, with parallel increases in aequorin light emission (from 68Ϯ8% to 138Ϯ18% in nonfailing and from 70Ϯ8% to 160Ϯ13% in failing myocardium, respectively; PϽ0.05 versus baseline; data not shown). Time to 50% decline of the aequorin light transient (baseline versus 0.1 mol/L ET-1) increased from 64Ϯ7 to 76Ϯ7 ms (PϽ0.05) in nonfailing and from 91Ϯ6 to 98Ϯ12 ms in failing myocardium (PϭNS). Time to 90% decline increased from 199Ϯ11 to 215Ϯ12 ms (PϭNS) and from 194Ϯ16 to 213Ϯ22 ms (PϭNS), respectively.
For comparing the subcellular mechanism of action of ET-1 and [Ca 2ϩ ] o , the relation between the concentrationdependent change in twitch force and aequorin light emission for both interventions is plotted in Figure 7 for nonfailing myocardium (according to Reference 27) . It becomes obvious that the increase in force after [Ca 2ϩ ] o is raised is associated with a proportional increase in aequorin light emission, whereas similar changes in force after ET-1 are associated with only minor increases in aequorin light emission.
Radioligand Binding Studies
ET receptors in human myocardium were characterized by competitive radioligand binding using 125 I-labeled ET-1 and unlabeled ET-1, which binds with similar affinity to ET A and ET B receptors, ET-3 with Ϸ100-fold higher affinity for the ET B receptor, and the selective ET A receptor antagonist BQ-123. Figure 8 shows average values from displacement experiments for increasing concentrations of ET-1, ET-3, and BQ-123 in left ventricular myocardial membrane preparations from 5 nonfailing and 7 DCM hearts. In DCM, compared with nonfailing myocardium, the remaining 125 I-labeled ET-1 binding in the presence of BQ-123 is significantly decreased, from Ϸ40% to 25%. Accordingly, the upper part of the ET-3 displacement curve is shifted rightward, indicating a low affinity of the ET B -specific ligand ET-3. LIGAND analysis of the individual experiments revealed both ET A and ET B receptors in human cardiac tissue, and the relative proportion of the ET A receptor increased from 63Ϯ5% in nonfailing to 73Ϯ3% in failing myocardium ( Table 2 .
Endothelin-1 Peptide Tissue Concentration
ET-1 peptide concentration was measured in left ventricular homogenates from 5 nonfailing and 5 end-stage failing hearts. ET-1 peptide concentration in nonfailing myocardium was 4541Ϯ1340 pg/mg protein (1.8Ϯ0.5 fmol/mg). ET-1 peptide concentration was significantly increased in DCM to 14 447Ϯ2232 pg/mg protein (5.8Ϯ0.9 fmol/mg; PϽ0.05 versus nonfailing).
Discussion
The main findings of this study are that (1) ET-1 exerts direct inotropic effects in human ventricle that are reduced in failing compared with nonfailing myocardium, (2) functional responses are mediated via ET A receptors and are not associated with significant increases in intracellular Ca 2ϩ transients, and (3) ET A receptor density and ET-1 peptide concentration are increased in DCM.
Functional Effects of ET-1
Direct positive inotropic effects of ET-1 have been described in rat, rabbit, and ferret [3] [4] [5] [6] [7] but not in guinea pig 8 or dog 6 myocardium. Recently, a direct inotropic effect of ET-1 has been reported for human atrial myocardium, 26 and a single concentration of ET-1 showed inotropic responses in muscle strips 18 and isolated myocytes 17 from failing human hearts. Furthermore, ET A and ET B receptors were demonstrated in human myocardium, and ET A receptor mRNA was recently found in human cardiac myocytes. 28 However, the exact characterization of the functional effects of ET-1 in nonfailing and failing human ventricles and the ET receptor subtype involved in this effect remained to be determined.
From this study, it is evident that ET-1 exerts a concentrationdependent inotropic response in nonfailing and failing myocardium. This effect is comparable to ␣-adrenergic receptor stimulation but is only 20% to 30% of the maximal inotropic effect that can be obtained with ␤-adrenergic receptor stimulation in human cardiac muscle. As assessed by ␣-and ␤-adrenergic receptor blockade, the inotropic response to ET-1 is independent of activation of these receptors. In contrast, the mixed ET receptor antagonist bosentan as well as the selective ET A receptor antagonist BQ-123 shifted the concentration-response curve for ET-1 to the right. In contrast, selective ET B receptor stimulation with sarafotoxin S6c did not elicit any inotropic response. These data suggest that the inotropic effect of ET-1 is mediated specifically and exclusively via ET A receptors located on ventricular myocytes. This is in contrast to the rat heart, in which ET B receptor-mediated inotropic effects of ET-1 have been reported. 29 
Endothelin Receptor Densities
Elevated ET plasma levels in patients with congestive heart failure 11,12,15 might influence ET receptor regulation. In contrast to observations in the ␤-adrenergic receptor system, 30 but similar to ␣-adrenergic receptors, 31 the present study shows increased cardiac ET receptor densities in DCM without changes in the affinity of the receptors for their ligands. The upregulation of ET receptors was due to a selective upregulation of ET A receptors with no change in ET B receptor density.
In animal models of heart failure, both upregulation and downregulation of ET receptors were reported. 32, 33 ET receptor densities in this study in DCM are similar to results from autoradiographic studies by Molenaar et al 19 in 4 failing human hearts. Corresponding to our data, a subtype distribution of 57% ET A and 43% ET B was observed. 19 Furthermore, autoradiographic experiments by Bax et al 20 in nonfailing human hearts revealed a subtype distribution of 53% ET A and 47% ET B receptors, but these data were not compared with failing myocardium.
In agreement with our binding data, Morawietz and Holtz (Department of Physiology, University of Halle, Germany) observed a significant upregulation of ET A -receptor mRNA in end-stage failing compared with nonfailing human myocardium (personal communication). However, our results seem to be in contrast to receptor binding data by Pönicke et al 21 in human cardiac tissue. These authors found a total ET receptor density of 113Ϯ27 fmol/mg protein in nonfailing myocardium. Using pooled myocardium from end-stage failing hearts due to both idiopathic dilative and ischemic cardiomyopathy, the authors detected an increase in ET receptor density to 147.5Ϯ44 fmol/mg protein, which was not significant. Interestingly, in their study, separate analysis of ET receptors according to pathogenesis of cardiac disease revealed a decline of ET receptors in ischemic (81.9Ϯ12 fmol/mg protein; nϭ5) but a 2-fold increase in dilative cardiomyopathy (213Ϯ82 fmol/mg protein; nϭ5). We also found a decline of ET receptor expression in ischemic cardiomyopathy (43.2Ϯ5.7 fmol/mg protein; nϭ6; unpublished data). Therefore, it seems possible that ET receptor expression is differentially regulated in dilative versus ischemic cardiomyopathy, and pooling of myocardium with both diseases might contribute to the lack of significance for the ET receptor increase in the study by Pönicke et al. 21 Because radioligand binding studies in myocardial homogenates do not allow us to discriminate between receptors on 34 ET receptor density is lower on fibroblasts than on myocytes, 35 and ET receptor number on smooth muscle cells does not exceed ET receptor number on myocytes. 36 Therefore, the observed marked upregulation of ET A receptors in DCM hearts most likely results from increased myocyte receptor density.
ET-1 Tissue Concentration
The existence of a local cardiac ET system has been postulated on the basis of the expression of preproET-1 mRNA 37 and peptide, 22 but no information about changes in peptide content in human failing myocardium is available. ET-1 exerts its local action in a paracrine and autocrine fashion 37 through secretion from endothelial cells toward their abluminal borders 38 and direct secretion from cardiac myocytes. 10 We detected a 3-fold increase in ET-1 peptide concentration in DCM, possibly indicating the activation of a local cardiac ET system. However, from our experiments in myocardial homogenates, we cannot localize ET-1 peptide overexpression to either endothelial cells, smooth muscle cells, or cardiac myocytes.
Subcellular Mechanism of Action of ET-1
It was previously reported that ET-1 induces phosphoinositide breakdown, 21 mediating protein kinase C activation and subsequent stimulation of Na ϩ -H ϩ exchange. 4 This results in intracellular alkalinization and sensitization of the myofilaments for Ca 2ϩ . Consistently, we did not detect significant increases in intracellular Ca 2ϩ after ET-1. Furthermore, we demonstrated that inhibition of protein kinase C or Na ϩ /H ϩ exchange prevented the inotropic response to ET-1 but not to isoproterenol in human atrial trabeculae. 28 Our findings of an ET-1-induced positive inotropic effect with only minor changes in intracellular Ca 2ϩ transients are in agreement with previous reports in animal experiments in ventricular tissue. ET-1 increases contractility but does not change intracellular Ca 2ϩ transients in isolated adult ventricular myocytes from rats 4 and rabbits. 39 In contrast, using isolated ferret papillary muscle, Wang and Morgan 40 demonstrated a slight, albeit significant, increase in [Ca 2ϩ ] i after ET-1 associated with a 64% increase in twitch force. Furthermore, Qiu et al 17 did not observe an increase in Indo-1 fluorescence associated with increased shortening after ET-1 in human myocytes. For human ventricular myocardium, our results suggest increased myofibrillar Ca 2ϩ responsiveness as the major mechanism of action of ET-1. However, we recently found a slight increase in aequorin light emission in human atrial trabeculae, 26 but different coupling of endothelin receptors in atrial compared with ventricular myocardium was described. 41 Therefore, we cannot exclude the possibility that small increases in intracellular Ca 2ϩ , possibly related to increased transsarcolemmal Ca 2ϩ influx 42 or mobilization of Ca 2ϩ from intracellular stores 43 contributes to the positive inotropic effect of ET-1 in human ventricular tissue.
Possible Mechanisms Underlying the Reduced Functional Effect of ET-1 in DCM
The present finding of a reduced inotropic effect of ET-1 in failing human myocardium is in agreement with a previous report in a rabbit heart failure model. 44 Downregulation of the ET A receptor is unlikely to contribute to reduced functional effects of ET-1, because we detected an increased expression and unchanged affinities of the ET A receptors in DCM. Accordingly, Pönicke et al 21 found unchanged inositol phosphate accumulation after ET-1 stimulation in failing compared with nonfailing myocardium. However, Freedman et al 45 recently described a rapid homologous ET A receptor desensitization by ET-1-induced activation of G protein-coupled receptor kinases and phosphorylation of the receptor. This process may be of importance in the light of increased ET-1 plasma levels in heart failure. Furthermore, the effectiveness of ET-1 to stimulate Na ϩ /H ϩ exchange activity was impaired in rat cardiac hypertrophy, resulting in blunted functional effects of ET-1. 46 This might indicate that alterations in subcellular mechanisms mediating functional responses of ET-1 could contribute to the reduced inotropic effect in diseased myocardium. However, few data regarding such defects were reported for human myocardium. Furthermore, because binding data in myocardial homogenates cannot provide final proof for an upregulation of ET A receptors on cardiomyocytes, the alterations underlying the reduced effectiveness of ET-1 in DCM deserve further investigation.
Clinical Relevance of the Endothelin System in Heart Failure
The relevance of an activated ET system for maintaining cardiac function has recently been shown for a rat infarct model of heart failure. 13 However, this may not completely translate into the situation of patients with chronic congestive heart failure, for several reasons: (1) in addition to its positive inotropic effects, ET-1 constricts coronary arteries and peripheral resistance vessels, thereby reducing coronary blood flow and increasing afterload, which might impair contractility 47, 48 ; (2) the inotropic effect of ET-1 is small and accounts for only 20% to 30% of the maximal ␤-adrenergic receptor-mediated inotropic effect in nonfailing and failing myocardium; and (3) short-term treatment of patients with severe congestive heart failure with the nonselective ET receptor antagonist bosentan resulted in favorable acute hemodynamic effects, 15 and long-term treatment with bosentan increased survival in a rat model of chronic heart failure. 49 Therefore, the beneficial effect of ET-1 on contractile performance in the human heart may be offset by increased load, reduced coronary blood flow, and induction of cardiac hypertrophy and remodeling, and treatment of heart failure patients with ET receptor antagonists may be beneficial despite the loss of ET-1-related positive inotropy.
